Sojournix is a biotechnology startup pioneering new treatments for women's health and endocrine disorders. Headquartered in an undisclosed location, the company was founded in 2016. In its most recent funding round on 04 January 2019, Sojournix secured a significant $44.00M in a Series C investment. Noteworthy investors in this round include RA Capital Management, Frazier Healthcare Partners, Boxer Capital, Janus Handerson, and Venrock Healthcare Capital Partners. With a focus on addressing critical health issues, Sojournix's innovative approach and strong investor backing position it as a promising player in the biotechnology and healthcare industries.
Sojournix
Pioneering new treatments for women's health and endocrine disorders
Founded 2016
1 employees
Series C
Total: $70.00M
Biotechnology, Health Care
General Information
Company Name
Sojournix
Founded Year
2016
Employees
1
Industries
Biotechnology, Health Care
Funding Stage
Series C
BounceWatch is an independent company data service, not affiliated with Sojournix. To contact Sojournix, visit sojournixpharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Sojournix compare?
A PDF of Sojournix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Sojournix soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Sojournix
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | $44.00M | 5 |
|
04 Jan 2019 |
| Series B | $19.00M | - |
|
21 Dec 2017 |
| Series A | $7.00M | - |
|
17 May 2017 |
Sojournix Alternatives & Competitors
View All Alternatives
Sojournix vs
Spruce Biosciences
United States
Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders
Post-IPO Equity
27 employees
Biopharma, Biotechnology
Sojournix vs
Neurolixis
United States
New treatments for central nervous system disorders
Seed
5 employees
Biopharma, Biotechnology
Sojournix vs
Pioneering treatments for kidney failure, renal disorders, and gastrointestinal diseases.
Venture round
1 employees
Biotechnology, Health Care
FAQ About Sojournix
Pioneering new treatments for women's health and endocrine disorders
Sojournix was founded in 2016.
Sojournix operates in Biotechnology and Health Care.
Sojournix has approximately 1 employees.
Sojournix has completed 3 funding rounds, raising a total of $70.00M. The latest funding stage is Series C.
Top alternatives and competitors to Sojournix include Spruce Biosciences, Neurolixis, NephRx Corporation, HemoShear Therapeutics, Versartis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Sojournix and Spruce Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Sojournix, https://bouncewatch.com/company/sojournix, updated 27 October 2024. When citing, please name BounceWatch and link this page.
